Business Wire India
Octapharma announced today a satellite seminar and poster presentation at the 14th Annual Conference of the European Union of Haemophilia and Allied Disorders (EAHAD), which will be held from approximately 3 to 5 February 2021.
Satellite seminar, A family trip with Nuvik®: Early Treatment Decisions for Long Term Health, Dr. Robert F. Sidonio Jr. will preside (Georgia Center of Bleeding and Clotting Disorders for Bleeding, Children’s Healthcare of Atlanta, Emory University, Atlanta, USA) and will follow a family treatment trip with two sons diagnosed with severe hemophilia. a. Speakers will make key treatment decisions and considerations in the context of the treatment landscape, including prevention and treatment of bleeders, obstructive risk, inhibitor elimination and bone and joint health. This seminar will be available through the EAHAD online platform on February 4, 2021 at 18:00 CET.
In a poster session, Dr. Sylvia Hornf (Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany) will present a single-central experience of bleeding management in 46 patients with acquired hemophilia A, including nine patients with a rare autoimmune The disorder is involved. Octal-treated®:
Poster ABS193 Safety and efficacy of high-dose plasma-derived FVIII in patients with acquired hemophilia A (Di Prinz GG et al.).
Larissa Bolyakaya, Head of IBU Hematology at Octaphera commented, “We are proud to share the real-life experience of the positive impact of Nuwiq® With hemophilia A in children, as well as clinical trial data in our portfolio, such experience helps inform treatment decisions, which are increasingly complex as new treatments.. “
Olaf Walter, a board member at Octapharma, said, “Our ultimate objective at Octpharma is to improve the lives of patients, and it is a real privilege to see our work achieve this goal. Our contribution to the EAHAD Congress highlights our commitment to enable people with hemophilia A to live a long, active and healthy life.“.
Headquartered in Lachen, Switzerland, Octapharma is one of the world’s largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide supporting the treatment of patients in 118 countries with products in three therapeutic areas: hematology, immunotherapy and critical care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of about 8 million liters of plasma per year. In addition, Octapharma operates more than 140 plasma donation centers throughout Europe and the Americas.
Nuwiq® (simoctocog alfa) is a fourth-generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other human protein.1. It is cultured without an additive of human or animal origin, devoid of antigenic non-human protein epitope and has a high affinity for von Willebrand factor.1. Nuwiq® The treatment has been evaluated in seven complete clinical trials involving 201 previously treated patients (PTPs; 190 individuals) with severe hemophilia A, including 59 children.1. Nuwiq® Available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU sessions2. Nuwiq® Approved for use in the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital FVIII deficiency) in all age groups2.
- Lissitchkov T et al. Hematol 2019 Advances; doi: 10.1177 / 2040620719858471
- Nuwiq® Summary of Product Characteristics.
octanate® A human plasma-derived, high purity, freeze-dry, double virus inactivated factor VIII (FVIII) concentrate for intravenous administration1,2. FVIII in octet® At a VWF / FVIII ratio of about 0.4, its natural stabilizer, von Willebrand Factor (VWF), is bound.1. Therefore, no additional stabilizers are required during manufacturing. octanate® Available in 250 IU, 500 IU and 1000 IU presentations1. octanate® The first was approved 20 years ago and has since been approved for the treatment of hemorrhage in patients with hemophilia A (congenital FVIII deficiency) in more than 85 countries, both prophylactic and of all age groups.1. This preparation is not an indication for von Willebrand’s disease. octanate® More than 40 countries are also indicated for immune tolerance induction (ITI)1.
- Klukowska A et al. Haemophilia 2018; 24: 221–8.
- octanate® Summary of Product Characteristics.
The content is by Business Wire India. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.